Ariad Pharmaceuticals, Inc. Announces Appointment of Senior Oncology Executive to Leadership Team

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Pierre F. Dodion, M.D., to the newly created position of senior vice president, oncology. In this role, Dr. Dodion will lead medical research, medical affairs, clinical operations, drug safety and pharmacovigilence and biostatistics and outcomes research at ARIAD. He will oversee the oncology clinical development programs for ARIAD’s lead product candidates – its novel mTOR inhibitor, AP23573, and its novel multi-targeted kinase inhibitor, AP24534 and will establish a medical affairs function to support U.S. marketing of oncology products. Dr. Dodion has over twenty-five years of experience in the global pharmaceutical industry and academia, most recently as executive director, oncology at Pfizer, Inc.

MORE ON THIS TOPIC